Fundraising Fox

PanTera

Mol, BE · 5 known investors

PanTera develops actinium-225, a therapeutic radioisotope used in precision cancer treatment through radiotheranostics, serving oncology patients and pharmaceutical companies globally. The company operates a production facility in Belgium producing high-purity actinium-225 as an active pharmaceutical ingredient for personalized nuclear medicine treatments.

Founders & leadership

SVSven van den berghe
Sven van den bergheinCEO
CMChristophe Malice
Christophe MaliceinCBO
SBSamy Bertrand
Samy BertrandinCTO
YSYves Sterckx
Yves SterckxinDirector of Finance & Administration
PV
Philippe VanwolleghemDirector Quality, Regulatory Affairs & HSE

Investors · 5

Competitors · 3

by search overlap

Companies competing with PanTera for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does PanTera do?
PanTera develops actinium-225, a therapeutic radioisotope used in precision cancer treatment through radiotheranostics, serving oncology patients and pharmaceutical companies globally. The company operates a production facility in Belgium producing high-purity actinium-225 as an active pharmaceutical ingredient for personalized nuclear medicine treatments.
Who are PanTera's investors?
PanTera's investors include EQT Life Sciences, Korys, Kurma Partners, LSP (Life Sciences Partners), PMV.
Where is PanTera headquartered?
PanTera is headquartered in Mol, BE.